Compare Huntington Bancshares Incorporated (HBAN) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Natera Inc. Common Stock — how do they compare? Huntington Bancshares Incorporated trades at $15.19 (market cap $30.79B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Huntington Bancshares Incorporated pays a 4.07% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and Natera Inc. Common Stock for 0 Days on average.
| HBAN | NTRA | |
|---|---|---|
Market Cap | $30.79B | $57.03B |
Volume | 16,522,211 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $19.27 | $425.64 |
52-Week Low | $15.02 | $179.42 |
Typical Hold Time | 52 Days | 0 Days |
Enterprise Value | $49.31B | $56.18B |
Dividend Yield | 4.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.10, down 1.95% amid bearish technical signals and recent earnings volatility. The stock shows mixed fundamentals with a P/E of 11.72 and ROE of 9.23%, while revenue grew to $8.13B in 2025. Recent news highlights margin pressures from higher interest rates and a reduced 2027 outlook, though the company maintains shareholder returns through dividends and buybacks.
HBAN presents a cautious near-term outlook with analyst consensus at $19.60 (30% upside potential) but faces headwinds from net interest margin compression. Investment opportunity lies in valuation discount to peers, while risks include prolonged rate pressures and execution challenges in loan growth. The balanced analyst rating (47% Buy, 47% Hold) reflects uncertainty around timing of recovery.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
